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Abstract Antipsychotics, risperidone, and risperidone’s
active metabolite, paliperidone (9-hydroxyrisperidone), are
related molecules used for the treatment of schizophrenia
and related disorders. Differences in receptor binding,
5-HT2A/D2 (serotonin/dopamine) binding ratios, and mi-
tochondrial proteomics suggest that the effects of risperi-
done and paliperidone on neuronal firing, regulation of
mitochondrial function, and movement are different. This
review seeks to explore the most significant differences at
the molecular level between risperidone and paliperidone,
as reported in preclinical studies. Although risperidone
shows higher affinity for 5-HT receptors, paliperidone does
not fit this profile. Thus, the risperidone 5-HT2A/D2 binding
ratio is significantly lower than the paliperidone 5-HT2A/D2
binding ratio. Paliperidone, similar to lithium and val-
proate, affects expression levels and phosphorylation of
complex I and V proteins in synaptoneurosomal prepara-
tions of rat prefrontal cortex, suggesting that paliperidone
behaves as a mood stabilizer. It is apparent that the pres-
ence of a hydroxyl group in the paliperidone molecule
confers increased hydrophilicity to this drug compared
with its parent, risperidone; thus, this contributes to dif-
ferential effects on mitochondrial movement, protein ex-
pression, and phosphorylation. These differences are
reflected in synaptic plasticity and neuronal firing and have
only recently been implicated in the mechanisms of mito-
chondrial function and movement.
Key Points
Differences in receptor binding between risperidone
and paliperidone have been reported by several
groups of investigators.
Risperidone and paliperidone exhibit differences in
5-HT2A/D2 (serotonin/dopamine) binding ratios.
Differences in mitochondrial proteomics between
risperidone and paliperidone at the synaptic level
have been reported.
Implications
The scientific literature from the last 10 years
suggests that the effects on neuronal firing,
regulation of mitochondrial function, and movement
at the synaptic level between risperidone and
paliperidone are different.
1 Introduction
Antipsychotics, risperidone, and risperidone’s active
metabolite, paliperidone (9-hydroxyrisperidone), are relat-
ed molecules used for the treatment of schizophrenia and
related disorders. Are there meaningful differences be-
tween risperidone and paliperidone? Despite their parent/
metabolite relationship, these two drugs are different by
chemical definition (Fig. 1). The presence of one hydroxyl
group (–OH) at position 9 in risperidone confers different
chemical and physical properties to the drug. The mole-
cular weight for the white crystalline solid risperidone is
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410.49 g/mol, with a melting point of 170 C, and the
molecular weight of the off-white to light-orange solid
paliperidone is 426.48 g/mol, with a melting point of
158–160 C (http://www.drugbank.ca). Paliperidone is ca-
pable of more hydrogen bonds with other molecules con-
taining hydroxyl groups, including water, contributing to
its low affinity for lipid-rich environments. This charac-
teristic is a determining factor not only for crossing the
blood–brain barrier (BBB) but also for the rate and degree
of metabolism. Does this ‘minor’ structural difference in
the risperidone molecule result in ‘major’ differences at the
synaptic level? Although clinical differentiation between
these related molecules has not been systematically or
thoroughly studied to date, several distinct preclinical
findings will be reviewed in this article.
Preclinical data suggest that risperidone and paliperi-
done are different in terms of neuroreceptor binding, mi-
tochondrial function, and movement, with consequences
for neuronal firing [1–9]. Although risperidone and
paliperidone have similar binding affinities for some re-
ceptor subtypes, several distinctions may be biologically
meaningful. The best characterized interaction is the one
that takes place between dopamine (D2) and serotonin (5-
HT2A) receptors. Relevant data for the affinity of both
risperidone and paliperidone in preclinical studies using
human cell lines (in vitro) or animal tissue have been
documented by various groups of investigators for a-a-
drenergic, dopaminergic, muscarinic, and serotonergic re-
ceptors [3, 5, 8–13]. Differences in the 5-HT2A/D2 affinity
ratio suggest that combined interaction with these two re-
ceptors might be different for each drug [3, 5, 14]. Sero-
tonin and dopamine have opposite effects on mitochondrial
movement [15]; therefore, it is reasonable to hypothesize
that differences in the 5-HT2A/D2 ratio will affect mito-
chondrial movement and, consequently, calcium home-
ostasis, synaptic plasticity, and neuronal firing.
To explore potential differences between paliperidone
and risperidone at the molecular level, with the goal of
improving understanding, a literature search was per-
formed that included information from 2001 to 2012 on
animal and cell culture studies related to these two drugs.
Earlier references were included only if they related to
in vitro testing or binding affinities.
2 Literature Review
Initial searches were performed through conventional
search engines such as Google Scholar and public
databases such as PubMed using the keywords ‘risperi-
done’ and ‘paliperidone’. The hits obtained were narrowed
by including specific restrictions such as [AND], [OR],
[NOT], and [AND][NOT]. A limit on the number of hits
was imposed by searching for studies reported from 2002
to 2012; however, earlier references were included when
they related to in vitro testing or binding affinities.
Risperidone has been available longer than paliperidone;
therefore, a substantial quantity of data on risperidone dates
back to the early 1990s. The effects of risperidone and
paliperidone on mitochondrial function, synaptic transmis-
sion, and cellular metabolism as they relate to bipolar disorder
and schizophrenia have been described only over the past
5 years. Published data related to these two drugs were found
by adding the following Medical Subject Heading (MeSH)
terms or their combinations: ‘schizophrenia’, ‘bipolar disor-
der’, ‘antipsychotic’, ‘neuroleptic’, ‘mood stabilizer’, ‘pre-
clinical’, ‘animal studies’, ‘pharmacokinetics’, ‘in vitro’,
‘in vivo’, ‘metabolism’, ‘receptor affinity’, ‘mitochondria’,
‘receptor’, ‘dopamine’, ‘serotonin’, ‘cell culture’, and ‘sy-
napse’. Only studies published in English that provided suf-
ficient experimental details to follow the protocols described
in each study were considered in this review.
Available reports on receptor binding from different
families were tabulated for comparison of the two drugs.
Receptor binding affinities were color coded (green or red)
on the basis of predetermined value ranges in order to il-
lustrate main differences. Ratios of 5-HT2A/D2 binding
affinity were calculated, and data relating these effects to
mitochondrial function and movement were compiled.
Affinity ratios were calculated only if each set of data was
obtained under the same experimental conditions for
comparison of the two drugs.
Fig. 1 a Risperidone is a benzisoxazole derivative whose molecular
formula is C23H27FN4O2. b Paliperidone or 9-hydroxy-risperidone is
the main active metabolite of risperidone, whose molecular formula is
C23H27FN4O3. The hydroxyl group (red circle) confers different
chemical and biochemical properties to the molecule
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In terms of genomic information, a search of Gene
Expression Omnibus (GEO) data sets and profiles
deposited at the National Center for Biotechnology Infor-
mation (NCBI) [http://www.ncbi.nlm.nih.gov] was per-
formed. This search included the keywords ‘risperidone’
[AND] ‘paliperidone’ and was not limited by year or other
MeSH terms. GEO profiles were searched using the words
‘bipolar disorder’ and ‘schizophrenia’. Transcripts de-
scribed in these studies corresponding to mitochondrial
complexes I and V were found by matching annotated gene
names and descriptors with names provided by the
Universal Protein Resource and gene cards V3 (http://
www.genecards.org). Transcript expression was analyzed
by exporting the values associated with each record to
generate an Excel 2010 (Microsoft Corporation, Redmond,
WA, USA) graph of controls versus schizophrenic or
bipolar subjects. In addition, data related to mitochondrial
function and movement were obtained as previously de-
scribed [7]. Briefly, mitochondrial protein expression and
phosphorylation were identified using two-dimensional
difference gel electrophoresis, Western blots, and nano-
liquid chromatography/mass spectrometry of synaptoneu-
rosomal preparations of rat prefrontal cortex (PFC) after
28 days of treatment with different doses of paliperidone
and risperidone. Proteins were clustered according to
function, and a model relevant to the main effects of these
two drugs at the synaptic level was constructed.
Information regarding differences between risperidone
and paliperidone or the effects of these two drugs on mi-
tochondrial function and movement was scarce at the time
of submission of this review. The number of publications
that included the word ‘paliperidone’ was significantly
smaller than the number of publications in which the word
‘risperidone’ appeared. This is not surprising, given that
paliperidone was much more recently approved for clinical
use. A search of the NCBI database revealed three GEO
data sets for the word ‘risperidone’ [16–18] and zero GEO
profiles or data sets for the words ‘paliperidone’ and
‘risperidone [AND] paliperidone’. The number of publi-
cations identified with the combined key words ‘risperi-
done’ [AND] ‘paliperidone’ [AND] ‘mitochondria’ was 93.
There were five publications (including posters) in which
the additional term ‘movement’, ‘migration’, or ‘transport’
appeared, along with the terms previously mentioned, but
only two proved to be relevant [1, 19].
3 Differences between Risperidone
and Paliperidone
Significant differences between the two drugs were found
at the preclinical level in receptor binding (affinity and
5-HT2A/D2 ratios) and synaptic mitochondrial effects
(effects on synaptoneurosomal mitochondrial protein ex-
pression, synaptoneurosomal protein phosphorylation, and
mitochondrial movement) with implications for neuronal
firing and neurogenesis [2].
3.1 P-Glycoprotein
P-Glycoprotein is an adenosine triphosphate (ATP)-de-
pendent key protein involved in drug efflux at the BBB [20,
21]. In animals, this transporter limits brain penetration of
several centrally active drugs, including methadone, olan-
zapine, risperidone, and paliperidone [22, 23].
P-glycoprotein knockout mouse models have revealed
that risperidone and paliperidone brain concentrations and
the ratio of brain-to-plasma concentration are significantly
higher in knockout mice versus wild-type animals [23, 24].
These results suggest that risperidone and paliperidone are
substrates of P-glycoprotein and that their disposition
might be influenced by the functional status of P-glyco-
protein. Although both risperidone and paliperidone are
substrates of P-glycoprotein, their entry into the brain is
dramatically limited by their interaction with P-glycopro-
tein in the BBB [23–25].
Studies on P-glycoprotein involving risperidone and
paliperidone are scarce. However, Zhu et al. [26] demon-
strated that risperidone and paliperidone increased the in-
tracellular accumulation of rhodamine 123 and doxorubicin
in a P-glycoprotein-overexpressing cell line (LLCPK1/
MDR1) in a dose-dependent manner. In this study,
risperidone exhibited much greater potency when com-
pared with paliperidone. The IC50 values (the concentration
of an inhibitor where the response, or binding, is reduced
by half) for risperidone in inhibiting P-glycoprotein-me-
diated transport of rhodamine 123 and doxorubicin were
63.26 and 15.78 M, respectively. The IC50 values for
paliperidone were greater than 100 lM [26]. These results
indicate that risperidone has greater potential to influence
pharmacokinetics and pharmacodynamics through inhibi-
tion of P-glycoprotein-mediated transport. Monolayers of
Caco-2 and primary cultured rat brain microvessel en-
dothelial cells, such as the small intestine and BBB in vitro
models, respectively, were used in the same study to
evaluate the possible influence of risperidone on absorption
and transport across the BBB [26]. Risperidone exhibited
an IC50 value of 5.87 lM. P-glycoprotein seems to be able
to efflux to a greater extent than paliperidone, which is
more hydrophilic compared with its parent compound.
These studies support the notion (in vitro) that paliperidone
appears to be a less potent P-glycoprotein inhibitor than
risperidone [26].
In a similar study, Caco-2/TC7 cell monolayers were
used to study the effects of 1 lg mL-1 risperidone on
apparent permeability in the presence or absence of various
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P-glycoprotein and cytochrome P450 (CYP) 3A4 inhibitors
(verapamil, ketoconazole, erythromycin), and of an asso-
ciated multidrug-resistant protein inhibitor (indomethacin).
Risperidone pharmacokinetic parameters were determined
by compartmental and deconvolution methods using in-
travenous and oral risperidone doses. 9-Hydroxyrisperi-
done formation was observed on Caco-2 cells after
risperidone administration. Results of these studies indicate
that P-glycoprotein decreases the intestinal absorption of
risperidone [27].
It is common knowledge in the pharmaceutical field that
in vitro and preclinical measurements of BBB drug
penetration do not always accurately predict in vivo in-
teractions in humans. However, in a recent study [28],
positron emission tomography (PET) measurements were
combined with in vitro equilibrium dialysis to determine
free brain concentrations of 36 drugs in vivo in the pig. The
predicted P-glycoprotein status of these drugs was consis-
tent with PET/equilibrium dialysis results, suggesting that
prediction of P-glycoprotein at the preclinical level might
be an accurate representation of the situation in a clinical
setting [28].
Differences between risperidone and paliperidone in
chemical structure might define the extent of the interaction
between these drugs and P-glycoprotein. In turn, this in-
teraction will influence drug availability in the brain and
receptor binding observed in clinical studies.
3.2 Differences in Receptor Binding
3.2.1 Receptor Binding Affinities
Regarding receptor binding, relevant data for the affinity of
both risperidone and paliperidone in studies using human
cell lines (in vitro) or animal tissue were found for a-
adrenergic, dopaminergic, muscarinic, and serotonergic
receptors, as shown in Table 1 [3, 5–9]. No reports were
found from the time period searched that described the
effects of these drugs on c-aminobutyric acidergic,
cholinergic, nicotinic, glutaminergic, metabotropic,
glycinergic, or b-adrenergic receptors. The manufacturer
has reported binding values for opioid receptor l (inhibi-
tion constant [Ki] = 3089 nM) [data on file, Janssen
Pharmaceuticals, Inc.].
Risperidone has shown increased selectivity for the an-
tagonism of 5-HT2A versus D2 receptors [13]. Its interac-
tions with histamine (H1) and a-adrenergic receptors have
been reported [3, 5, 9]. Documentation on interactions with
cholinergic receptors (muscarinic) is rare, and the Ki values
reported are as high as 10,000 nM [3, 5, 10], indicating no
significant interaction. In a similar manner, paliperidone
antagonizes D2 and 5-HT2A receptors [5]. It has been
suggested that antagonism at a1- and a2-adrenergic and H1
receptors may contribute to therapeutic response, as well as
to adverse effects observed with the drug. It has been re-
ported that paliperidone exhibits weaker affinity for a1-
and a2-adrenergic receptors when compared with risperi-
done in vitro in studies in which comparisons were made
using the same model and experimental conditions [7].
Other reports suggest that paliperidone possesses no affi-
nity for cholinergic, muscarinic, and b1- and b2-adrenergic
receptors [8]. Similar to risperidone, paliperidone has an
affinity for 5-HT1D, 5-HT2B, 5-HT7, and D3 receptors, as
shown in Table 1. The inhibition constant values for
binding to D2 and 5-HT2A receptors are lower for
paliperidone than for risperidone (0.16 vs. 5.9 nM and 0.25
vs. 4.8 nM, respectively) [8, 11, 12].
Although Ki values considered pharmacologically ir-
relevant were found during research for this review, these
values were included to generate a color coded represen-
tation of affinity for the two drugs to illustrate this com-
parison. Only relevant receptors described in the literature,
with Ki values available for both drugs, are included in
Fig. 2 [3, 5]. A cutoff value of 3.0 nM was assigned as the
limit for significant interactions, as values around this
number have been reported for D2 receptor affinity.
Results of preclinical studies in animal models suggest
that paliperidone and risperidone may differentially affect
neuronal firing at the synapse on the basis of serotonin and
norepinephrine receptor affinity [4]. These differences may
seem subtle at first but become more evident when reports
from different research groups are compared independent
of experimental conditions, as shown in Fig. 2. Low Ki
values indicative of high affinity were color coded using
different shades of green. Lighter green indicated the
highest affinity in a range from 0.0–1.0 nM. Although
changes are seen according to the model used, paliperidone
generally exhibits a lower Ki value for D2 receptors when
compared with risperidone. These observations are con-
sistent with results obtained by other groups of investiga-
tors [29–31]. Other differences noted include lower affinity
of risperidone for 5-HT7 receptors when compared with
paliperidone. It is also evident that both drugs have a
higher affinity for 5-HT2A receptors when compared with
other families of receptors, as indicated by the green color
in the scheme. The Ki values reveal that the affinity of
risperidone for this receptor is higher than that of
paliperidone. This result is consistent with evidence pre-
sented by other groups [30, 31].
3.2.2 5-HT2A/D2 Binding Affinity Ratios
A suitable indicator for binding affinity differences be-
tween risperidone and paliperidone was originally provided
by another author [14]. In this review, the authors men-
tioned that ‘‘the atypical character of antipsychotics relates
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to an increased affinity (antagonism) to 5-HT2A receptors
compared to D2 ones’’. This statement reflects a general
conception in clinical practice regarding atypical antipsy-
chotics, and it implies that for an atypical antipsychotic to
be effective the 5-HT2A/D2 affinity ratio should be lower
than 1.0, as is usually observed.
Values for 5-HT2A and D2 affinity vary depending on
the study, type of tissue, duration of treatment, and animal
and other variables; therefore, a calculation of 5-HT2A/D2
affinity ratios was performed for studies using the same
types of cells or tissues, under the same conditions, for both
drugs according to the values shown in Table 1. The results
of these calculations for two separate studies, as shown in
Table 2, illustrate this concept [3, 5]. As seen in Table 2,
the 5-HT2A/D2 affinity ratio for both drugs is lower than
1.0. However, the ratio for risperidone is 5–10 times lower
than for paliperidone, suggesting that risperidone may be-
have differently from paliperidone. These differences in
binding affinity ratios are related not only to differences in
direct pharmacologic effects of the drugs but also to dif-
ferences in mitochondrial function, as described in the next
section.
Table 1 Summary of receptor
binding affinities expressed as
Ki values (nM) for risperidone
and paliperidone
Receptor family Subtype Risperidone Paliperidone
Histaminergic H1 20.0
a, 34.0b, 20.0c, 2.6d, 5.2e, 5.2f 34.0b, 19.0c, 10.0d, 3.4e, 3.4f
H2 855.0
b, 120.0c 4627.0b, 121.0c
Adrenergic a-1a 8.0b, 5.0c, 2.7f 11.0b, 2.5c, 10.1f




a, 580.0b, 244.0c 554.0b, 41.0c
D2 4.0




a, 18.0b, 8.0c 7.5b, 3.5c
D4 9.0












e, 0.5a, 0.49b, 0.34c, 0.15f 1.2e, 0.83b, 1.1c, 1.21f
5-HT2C 25.0,




b, 206.0c 1495.0b, 278.0c
5-HT6 4118.0
b, 2057.0c 3425.0b, 2414.0c
5-HT7 1.8











Low Ki values indicate high affinity. Affinity ratios were calculated only if each set of data was obtained
under the same experimental conditions for a comparison of the two drugs
Ki inhibition constant
a Seeger et al. [9]
b Manufacturer-provided information
c Gray and Roth [5]
d Schotte et al. [8]
e Correll [3]
f Richelson and Souder [7]
g Knight et al. [6]
Comparative Pharmacology of Risperidone and Paliperidone 167
4 Synaptoneurosomal Differences
4.1 Mitochondrial Protein Expression
and Phosphorylation
Recent studies have revealed that, in the rat, long-term
treatment with paliperidone resulted in changes in mito-
chondrial protein expression similar to those seen with
lithium at the synaptoneurosomal level in the PFC, sug-
gesting that paliperidone behaves as a mood stabilizer [1].
Similar data have shown that changes in expression of
select subunits of complexes from the electron transport
chain (ETC) were opposite in synaptoneurosomal prepa-
rations from animals treated for 28 days with risperidone
and paliperidone; in some cases, these changes were dose-
dependent [32]. Subunits from complexes I, III, and V were
affected by these two drugs. Expression of mitochondrial
proteins NDUFS4 (complex I) and ATP5A1 (complex V)
was differentially affected by paliperidone and risperidone
in a dose-dependent manner. Cytoskeletal, mitochondrial,
and regulatory proteins whose expression and phosphory-
lation levels changed by at least sevenfold in response to
long-term paliperidone and risperidone treatment have
been reported [32]. Although some proteins were
upregulated in the paliperidone-treated group by twofold or
greater compared with the risperidone-treated group, others
remained unchanged.
It is interesting to note that the same two proteins dif-
ferentially expressed after risperidone and paliperidone
treatment in the rat PFC correspond to those differentially
expressed in patients with bipolar disorder and
schizophrenia, as is shown by gene expression data in
postmortem brain studies [16–18]. Genes coding for pro-
teins NDUFS4 and ATP5A1 have different expression
profiles in postmortem brain studies of schizophrenic and
bipolar subjects, according to the deposited GEO profiles.
Expression of ATP5A1 appeared to be reduced in patients
with schizophrenia compared with those with bipolar dis-
order. The opposite was observed for NDUFS4 [33].
4.2 Mitochondrial Movement
Mitochondrial dynamics is a recently developed field of
study. Over the past 5 years, few reports have described
associations between mitochondrial movement and the in-
fluence of dopamine and serotonin in its regulation. Mi-
tochondrial trafficking has now been linked to changes in
the activity of neurons modulated by serotonin and dopa-
mine [34–36]. Serotonin and dopamine have opposite ef-
fects on mitochondrial movement in terms of direction
[15]. Serotonin promotes anterograde movement toward
axons and dendritic terminals, and dopamine inhibits mi-
tochondrial transport [37]. Risperidone and paliperidone
exhibit differences in 5-HT2A/D2 affinity ratios; therefore,
the availability of serotonin and dopamine will also change
within synapses upon treatment. The authors hypothesize
that in addition to influencing mitochondrial function, ob-
served differences in 5-HT2A/D2 ratios between risperidone
and paliperidone are directly related to their differential
effects on the extent of mitochondrial movement. More
important, these drugs will affect the direction of such
movement in subtle but different ways, with paliperidone
promoting anterograde movement.
The mode of action of these drugs extends beyond the
traditional mode of action of antipsychotics in receptor
binding and synaptic plasticity. Each drug or drug combi-
nation will have different influences on serotonin and
dopamine levels, and consequently on the direction and
extent of mitochondrial movement.
The relationship between risperidone, paliperidone, and
mitochondrial movement has not been demonstrated in
animal models. However, treatment with lithium and
paliperidone cells in culture resulted in similar anterograde
Fig. 2 Comparison of the binding affinity of risperidone (R) and
paliperidone (P) with different receptors in two studies. Only relevant
receptors described in the literature with Ki values available for both
drugs were included. A cutoff value of 3.0 nM was assigned as the
limit for significant interactions as values around this number have
been reported for D2 receptor affinity. Green represents significant
interactions (from Correll [3] [Study 1] and Gray and Roth [5] [Study
2]). Ki inhibition constant
Table 2 5-HT2A/D2 affinity ratios calculated after two separate
preclinical studies involving risperidone (R) and paliperidone (P)
Drug used Study 1 Study 2
R P R P
Ki (nM) for 5-HT2A 0.15
a 1.2a 0.34b 1.1b
Ki (nM) for D2 3.8
a 2.8a 2.4b 1.6b
5-HT2A/D2 affinity ratio 0.04 0.43 0.14 0.69
Ki inhibition constant
a Correll [3]
b Gray and Roth [5]
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mitochondrial migration and preservation of mitochondrial
morphology. In contrast, treatment with clozapine and
haloperidol induced a ‘ballooning’ effect and gathering of
mitochondria around the nucleus [19]. These results sug-
gest that although mood stabilizers (lithium and valproate)
enhanced mitochondrial anterograde movement, antipsy-
chotics (haloperidol and clozapine) did not promote this
migration. These results also support the notion that
paliperidone behaves similarly to a mood stabilizer in
promoting anterograde mitochondrial movement.
Studies of phosphorylated proteins in rat PFC synap-
toneurosomal preparations revealed phosphorylation of
actin and tubulin isoforms. Phosphorylation of actin and
tubulin has been related to mitochondrial migration;
therefore, these results are also indicative of differential
effects of paliperidone on mitochondrial movement [32,
37]. Mitochondrial movement in opposite directions has
completely different consequences in calcium homeostasis
and neuronal firing, which, in turn, are reflected in phys-
iologic and clinical implications.
5 Neuronal Firing and Synaptic Plasticity
It is well-established that mitochondrial dysfunction leads
to alterations in synaptic strength and plasticity [38], and it
has been proposed that mitochondrial dysfunction in
schizophrenia could cause or arise from anomalies in
processes of plasticity in this disorder.
The strongest evidence of differences at the synaptic
level has been observed in neuronal firing and synaptic
activity studies involving short-term and semi-long-term
administration of risperidone and paliperidone. Only
risperidone inhibited firing of serotonergic neurons in
Sprague–Dawley rats. Semi-long-term (2–14 days)
risperidone administration inhibited firing of serotonergic
neurons with or without escitalopram, a selective serotonin
reuptake inhibitor. In the same study, paliperidone did not
alter the firing rate of norepinephrinergic neurons, and it
reversed suppression of norepinephrinergic neurons in-
duced by escitalopram, indicating that despite their simi-
larities in receptor binding, risperidone and paliperidone
differentially altered firing of serotonergic and nore-
pinephrinergic neurons in vivo [4].
The importance of serotonin in schizophrenia, mito-
chondrial movement, and the mechanism of action of an-
tipsychotic drugs highlights the need for future research in
this area.
Evidence of differences in synaptic plasticity and neu-
roprotection between the two drugs was found in studies
involving the subventricular zone (SVZ). This is an iden-
tified region for neurogenesis in the adult brain. Interacting
cell types and extracellular molecules present in this region
of the brain promote cellular proliferation [39]. It has been
reported that the SVZ also contains the largest population
of proliferating cells in the adult brain of rodents, monkeys,
and humans [40]. The differential effects of several an-
tipsychotics on the SVZ in rats were investigated in parallel
studies that included risperidone and paliperidone admin-
istration for 28 days [41]. Changes in neurogenic regions
have been related to tissue regeneration and improvement
in synaptic neurotransmission as some of the benefits of
antipsychotic treatment. It was observed in one of these
studies that paliperidone, but not risperidone, resulted in
increased numbers of cells in the posterior SVZ. Proteomic
studies in the rat PFC have also highlighted the neuro-
protective effects of paliperidone [1].
6 Current and Future Developments
At the preclinical level, risperidone and paliperidone ex-
hibit different BBB penetration on the basis of their in-
teractions with P-glycoprotein; this might prove to be an
accurate representation of their interactions in clinical
settings. These drugs also exhibit differences in binding
affinities for 5-HT2A and D2 receptors, as reflected by
different affinity ratios (5-HT2A/D2) under similar ex-
perimental conditions within the same model (rodent or
cell culture). Additional differences regarding the effects of
these two drugs on neuronal firing, mitochondrial protein
expression, and phosphorylation have been reported [1, 4,
32]. These differences have been related to mitochondrial
movement [2, 19, 32]. It is interesting to note that P-gly-
coprotein is a protein expressed on the mitochondrial
membrane that has been linked to drug efflux from the
mitochondria [42, 43]. Mitochondrial function and move-
ment as well as drug efflux and its regulation are not often
examined, despite recommendations on the importance of
considering neuroleptic influences on mitochondrial func-
tion [44–48].
This review has illustrated that differences observed in
preclinical studies involving risperidone and paliperidone
extend beyond pharmacodynamics and pharmacokinetics
into the molecular arena, and as deep as into the inner
mitochondrial membrane. These two drugs affect differ-
ential expression of subunits from complexes I and V of the
ETC that are crucial for maintaining neuronal homeostasis
(Fig. 3).
It has been suggested that mitochondrial dysfunction
underlies the pathophysiology of neurologic disorders such
as schizophrenia [49–55]. It has been demonstrated that
antipsychotics inhibit complex I activity after long-term
administration to rats or after in vitro addition to disrupted
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mitochondria [56–59]. Haloperidol potently inhibits com-
plex I in mouse brain slices, followed by chlorpromazine,
fluphenazine, and risperidone [60]. Impairment of complex
I in bipolar patients has also been documented [61].
Significant differences in 5-HT2A/D2 affinity ratios
have been noted between paliperidone and risperidone.
These differences are directly linked to the availability of
serotonin and dopamine at the synapse. Because serotonin
and dopamine are involved in the regulatory mechanism
of mitochondrial movement direction [15], it is an-
ticipated that risperidone and paliperidone will have dif-
ferent effects on mitochondrial movement. The effects of
these drugs in different regions of the brain and in neu-
ronal populations should be further explored in terms of
mitochondrial function and its relationship to neuronal
firing.
Neuronal firing may occur through energy release from
glucose (ATP generation through complex V) as a result of
mitochondrial function through the ETC. Therefore,
changes in mitochondrial function and movement to the
synapse will have profound effects on ATP production and
subsequently on neuronal firing. The direction and extent
of mitochondrial anterograde movement, as well as mito-
chondrial function, are likely regulated by interactions
between risperidone and paliperidone with 5-HT2A and D2
receptors. As the affinity ratios revealed, these interactions
are different for each of these drugs, suggesting that they
have differential effects on synaptoneurosomal energetics
(Fig. 4).
Parent drugs and metabolites usually have different
abilities to penetrate the BBB according to their chemical
structure, hydrophobicity, and orientation of functional
groups, with different manifestations at preclinical and
clinical levels. One hydroxyl group can change the hy-
drophilic/hydrophobic nature of a molecule and can have a
profound influence in terms of membrane permeability. In
addition, functional groups determine the interaction of
drugs with biological molecules as small changes in
structure typically result in significant changes in confor-
mation and orientation.
Examples of these differences include parent/metabolite
duos such as terfenadine/fexofenadine and ibogaine/nori-
bogaine [62, 63], shown in Fig. 5. Although both terfe-
nadine and its metabolite fexofenadine are antihistamines,
research has shown that after oral administration, fexofe-
nadine provided better protection than terfenadine against
the immediate allergic reaction [64]. Fexofenadine was
found to be a more selective histamine antagonist than
terfenadine. Similarly, the in vitro pharmacology of nori-
bogaine differs significantly from that of ibogaine. For
example, noribogaine displays a higher affinity for 5-HT
transporters and opioid receptor subtypes when compared
Fig. 3 Risperidone and
paliperidone induced
differential expression of key
subunits of the ETC complexes
I (NDUFS4) and V (ATP5H),
shown in this figure in purple,
suggesting differential
regulation of mitochondrial










with ibogaine [62]. Characteristics such as lipophilicity and
orientation of functional groups determine how these par-
ent/metabolite pairs are partitioned within specific com-
partments to reach particular targets.
Differences observed in animal and cell culture studies
about receptor binding, affinity ratios, synaptoneurosomal
proteomics, mitochondrial protein phosphorylation, neu-
ronal firing, and neurogenesis support the notion that
Fig. 4 As described in 2013 by Corena-McLeod and collaborators,
paliperidone-induced phosphorylation of actin, tubulin, and other
filaments promoting mitochondrial anterograde transport. a Serotonin
(blue spheres) promotes this anterograde movement. b Dopamine
(red spheres) has been shown to inhibit mitochondrial anterograde
transport
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risperidone and paliperidone behave as two different drugs.
Although preclinical work supports the differences be-
tween these two drugs, clinical differentiation warrants
further studies, and additional preclinical studies and data
should be obtained through studies of serotonin and
dopamine release at the synapse in relation to the direction
of mitochondrial movement after risperidone and
paliperidone treatment.
This review of the literature illustrates that significant
differences reflect synaptic plasticity and neuronal firing
and have only recently been implicated in the mechanism
of mitochondrial function and movement. This article
presents a review of the most significant differences at the
molecular level between risperidone and paliperidone, as
reported in preclinical studies.
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